Structure-Function Analysis of Phenylpiperazine Derivatives as Intestinal Permeation Enhancers
A major obstacle preventing oral administration of macromolecular therapeutics is poor absorption across the intestinal epithelium into the bloodstream. One strategy to improve transport across this barrier is the use of chemical permeation enhancers. Several molecular families with permeation enhancing potential have been identified previously, including piperazines. In particular, 1-phenylpiperazine has been shown to enhance transepithelial transport with minimal cytotoxicity compared to similarly effective molecules. To better understand how the chemistry of 1-phenylpiperazine affects its utility as an intestinal permeation enhancer, this study examined a small library of 13 derivatives of 1-phenylpiperazine.
The efficacy and cytotoxicity of 13 phenylpiperazine compounds were assessed in a Caco-2 model of the intestinal epithelium. Efficacy was measured using the paracellular diffusion marker calcein as well as by immunostaining and confocal imaging of Caco-2 monolayers.
Of the 13 derivatives, two enhanced the permeability of the fluorescent marker calcein over 100-fold. It was found that hydroxyl or primary amine substitutions on the phenyl ring significantly increased toxicity, while aliphatic substitutions resulted in efficacy and toxicity profiles comparable to 1-phenylpiperazine.
Several potent derivatives, including 1-methyl-4-phenylpiperazine and 1-(4-methylphenyl)piperazine, displayed lower toxicity than 1-phenylpiperazine, suggesting promise in future applications.
Key Words1-phenylpiperazine Caco-2 oral delivery permeation enhancer piperazine derivatives
Bovine serum albumin
Basal seeding medium
Dulbecco’s Modified Eagle’s Medium
Enterocyte differentiation medium
Methyl thiazole tetrazolium
Trans-epithelial electrical resistance
Acknowledgements and Disclosures
Funding was provided by the Center for Polymer-Based Protein Engineering and the Department of Chemical Engineering at Carnegie Mellon University.
- 1.Moroz E, Matoori S, Leroux J-C. Oral delivery of macromolecular drugs: where we are after almost 100 years of attempts. Adv Drug Deliv Rev Elsevier BV. 2016; http://linkinghub.elsevier.com/retrieve/pii/S0169409X16300278
- 4.Guggi D, Kast CE, Bernkop-Schnürch A. In vivo evaluation of an oral Salmon calcitonin-delivery system based on a Thiolated chitosan carrier matrix. Pharm Res 2003;20(12):1989–1994. http://download.springer.com/static/pdf/545/art%3A10.1023%2FB%3APHAM.0000008047.82334.7d.pdf?originUrl, http://link.springer.com/article/10.1023/B:PHAM.0000008047.82334.7d&token2=exp=1475174816~acl=/static/pdf/545/art%253A10.1023%252FB%253APHAM.0000008047.
- 6.Suzuki T. Regulation of intestinal epithelial permeability by tight junctions. Cell Mol Life Sci. 2013;70(4):631–59. doi: 10.1007/s00018-012-1070-x.
- 10.Pridgen EM, Alexis F, Kuo TT, Levy-Nissenbaum E, Karnik R, Blumberg RS, et al. Transepithelial transport of Fc-targeted nanoparticles by the neonatal fc receptor for oral delivery. Sci Transl Med. 2013;5(213):213ra167. http://stm.sciencemag.org/content/5/213/213ra167.short CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Shaquiquzzaman M, Verma G, Marella A, Akhter M, Akhtar W, Khan MF, et al. European Journal of medicinal chemistry Piperazine scaffold : a remarkable tool in generation of diverse pharmacological agents relative light units. Eur J Med Chem Elsevier Masson SAS. 2015;102:487–529. doi: 10.1016/j.ejmech.2015.07.026.CrossRefGoogle Scholar